Amanta Healthcare Ltd

Amanta Healthcare Ltd has a debt-to-equity ratio of 2.12, indicating a capital structure that is significantly leveraged. The company's liquidity position is assessed as medium, with a current ratio of 1.2, suggesting limited short-term liquidity cushion. Free cash flow for the period was INR 81.26 million, but capital expenditures were negative at INR 207.74 million, indicating asset disposals or reduced investment. Profitability metrics show a return on equity of 10.89% and a return on assets of 2.75%, both below the typical thresholds for pharmaceutical firms, which often require higher returns to justify R&D and regulatory costs. Operating income of INR 415.54 million and net income of INR 105.01 million reflect a narrow margin structure, with gross profit at INR 1.77 billion, or 64.3% of revenue. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond India. This lack of diversification increases exposure to domestic regulatory and economic shifts, which are common in the pharmaceutical industry. Growth trajectory appears muted, with no disclosed revenue growth rates or forward-looking guidance in the latest financials. The company's capital expenditures were negative, suggesting a reduction in investment, which could signal a strategic shift or financial constraint. Risk factors include a high debt load, with long-term debt of INR 2.04 billion, and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include the filing of the latest financial results, which show a decline in free cash flow and capital expenditures. No major regulatory or litigation events were disclosed in the latest filings.